k141_121492_2	SARG|U82085.gene.p01	30.2	205	287	552	1.93e-10	60.1
k141_121492_2	SARG|gi|488325511|ref|WP_002394896.1|	23.2	211	287	498	8.08e-09	55.1
k141_121492_2	SARG|AXF35727.1	21.4	238	287	497	1.44e-08	54.3
k141_121492_2	SARG|gi|895819918|ref|WP_048943810.1|	22.7	211	287	498	1.44e-08	54.3
k141_121492_2	SARG|gi|498424272|ref|WP_010730861.1|	22.7	211	287	498	1.44e-08	54.3
k141_121492_2	SARG|gi|514888562|ref|WP_016618095.1|	23.7	211	287	498	1.44e-08	54.3
k141_121492_2	SARG|gi|488311349|ref|WP_002380734.1|	22.7	211	287	498	1.93e-08	53.9
k141_121492_2	SARG|gi|488306124|ref|WP_002376519.1|	22.7	211	287	498	1.93e-08	53.9
k141_121492_2	SARG|gi|727118387|ref|WP_033626720.1|	22.7	211	287	498	1.93e-08	53.9
k141_121492_2	SARG|gi|498528849|ref|WP_010828356.1|	22.7	211	287	498	1.93e-08	53.9
k141_144258_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.7	231	224	235	3.04e-48	157
k141_144258_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.8	218	224	219	2.75e-45	149
k141_144258_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	224	231	9.66e-43	143
k141_144258_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.9	229	224	231	2.72e-42	142
k141_144258_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	224	231	1.34e-39	135
k141_144258_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	224	231	1.34e-39	135
k141_144258_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.5	223	224	228	6.91e-39	133
k141_144258_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	229	224	231	1.05e-38	132
k141_144258_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.8	224	224	229	3.23e-33	118
k141_144258_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.6	223	224	225	1.25e-31	114
k141_144258_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.0	216	225	255	1.21e-63	197
k141_144258_4	SARG|gb|AAV85982.1|ARO:3000535|macB	44.2	224	225	644	9.95e-52	176
k141_144258_23	SARG|ZP_04081918	29.8	225	512	306	6.52e-17	80.5
k141_144258_23	SARG|gi|447195835|ref|WP_001273091.1|	29.3	225	512	306	2.14e-16	79.0
k141_144258_23	SARG|gi|447195836|ref|WP_001273092.1|	29.3	225	512	306	2.14e-16	79.0
k141_144258_23	SARG|gi|507050365|ref|WP_016121371.1|	28.9	235	512	309	1.32e-15	76.6
k141_144258_23	SARG|gi|488053456|ref|WP_002124853.1|	28.9	228	512	309	1.32e-15	76.6
k141_144258_23	SARG|gi|507023808|ref|WP_016095885.1|	28.5	228	512	309	1.32e-15	76.6
k141_144258_23	SARG|gi|447057510|ref|WP_001134766.1|	28.5	228	512	309	1.32e-15	76.6
k141_144258_23	SARG|gi|446026113|ref|WP_000103968.1|	26.9	227	512	306	1.71e-15	76.3
k141_144258_23	SARG|gi|447057509|ref|WP_001134765.1|	28.1	231	512	309	1.77e-15	76.3
k141_144258_23	SARG|gi|445996710|ref|WP_000074565.1|	28.6	224	512	309	1.77e-15	76.3
k141_144258_27	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.4	109	528	228	3.28e-06	47.4
k141_144258_33	SARG|gi|502669352|ref|WP_012905216.1|	36.2	224	285	648	4.35e-39	143
k141_144258_33	SARG|gi|736472622|ref|WP_034494292.1|	36.6	224	285	648	4.35e-39	143
k141_144258_33	SARG|gi|1035717981|ref|WP_064557480.1|	36.2	224	285	648	1.12e-38	142
k141_144258_33	SARG|gi|803568669|ref|WP_046077412.1|	36.2	224	285	648	1.54e-38	142
k141_144258_33	SARG|gi|446110352|ref|WP_000188207.1|	36.2	224	285	648	1.54e-38	142
k141_144258_33	SARG|YP_002382193	36.2	224	285	648	1.54e-38	142
k141_144258_33	SARG|gi|803575554|ref|WP_046081557.1|	36.2	224	285	648	1.54e-38	142
k141_144258_33	SARG|gi|446110351|ref|WP_000188206.1|	36.2	224	285	648	1.54e-38	142
k141_144258_33	SARG|gi|1035706844|ref|WP_064548272.1|	36.6	224	285	648	2.91e-38	141
k141_144258_33	SARG|gi|1035670474|ref|WP_064517458.1|	36.2	221	285	648	7.50e-38	140
k141_144258_66	SARG|gb|AJD73064.1|ARO:3001301|RlmA(II)	36.4	264	266	282	4.40e-43	147
k141_144258_66	SARG|gb|AAD12162.1|ARO:3001299|tlrB	28.4	278	266	280	6.01e-24	96.7
k141_144258_66	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	28.4	278	266	280	6.01e-24	96.7
k141_144258_66	SARG|gb|AAS79458.1|ARO:3001302|chrB	29.7	286	266	280	5.99e-23	94.0
k141_144258_66	megares|MEG_4106|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	28.6	259	266	295	3.44e-19	84.0
k141_144258_66	SARG|gb|BAA03674.1|ARO:3001300|myrA	28.6	259	266	295	3.44e-19	84.0
k141_144258_72	SARG|gi|803568669|ref|WP_046077412.1|	28.0	232	271	648	9.59e-21	90.5
k141_144258_72	SARG|gi|446110352|ref|WP_000188207.1|	28.0	232	271	648	9.59e-21	90.5
k141_144258_72	SARG|YP_002382193	28.0	232	271	648	9.59e-21	90.5
k141_144258_72	SARG|gi|803575554|ref|WP_046081557.1|	28.0	232	271	648	9.59e-21	90.5
k141_144258_72	SARG|gi|446110351|ref|WP_000188206.1|	28.0	232	271	648	9.59e-21	90.5
k141_144258_72	SARG|gi|502669352|ref|WP_012905216.1|	28.0	232	271	648	4.34e-20	88.6
k141_144258_72	SARG|gi|1035670474|ref|WP_064517458.1|	26.3	232	271	648	3.26e-17	80.1
k141_144258_72	SARG|gi|1035717981|ref|WP_064557480.1|	26.3	232	271	648	3.26e-17	80.1
k141_144258_72	SARG|gi|736472622|ref|WP_034494292.1|	25.9	232	271	648	1.97e-16	77.8
k141_144258_72	SARG|gi|1035706844|ref|WP_064548272.1|	25.4	232	271	648	8.78e-16	75.9
k141_49883_17	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.5	234	207	648	9.17e-21	88.6
k141_49883_17	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	25.9	193	207	504	1.02e-12	65.1
k141_49883_17	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	36.4	99	207	550	1.32e-10	58.9
k141_49883_17	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	30.7	75	207	552	2.39e-07	49.3
k141_49883_17	SARG|gb|MBW0764195.1|ARO:3007027|salC	20.5	205	207	541	1.41e-06	47.0
k141_163356_2	SARG|gb|ABA71733.1|ARO:3002972|vanTG	33.5	370	382	712	1.25e-56	196
k141_163356_2	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	32.4	370	382	712	2.32e-55	192
k141_163356_2	SARG|gi|498467693|ref|WP_010773049.1|	32.6	365	382	700	6.32e-51	180
k141_163356_2	SARG|FJ872411.1.gene43.p01	31.8	365	382	702	2.66e-47	170
k141_163356_2	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	31.6	370	382	711	2.87e-47	170
k141_163356_2	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	31.8	314	382	700	8.82e-40	149
k141_163356_2	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	29.2	359	382	700	7.77e-39	146
k141_163356_2	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.6	314	382	700	1.49e-36	139
k141_163356_2	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.6	314	382	706	3.82e-36	138
k141_152078_14	SARG|gi|447195835|ref|WP_001273091.1|	36.3	245	288	306	3.93e-38	135
k141_152078_14	SARG|gi|447195836|ref|WP_001273092.1|	35.9	245	288	306	1.08e-37	134
k141_152078_14	SARG|ZP_04081918	35.2	253	288	306	4.17e-37	132
k141_152078_14	SARG|gi|500448961|gb|EOP61695.1|	33.2	256	288	306	5.84e-37	132
k141_152078_14	SARG|gi|447057509|ref|WP_001134765.1|	32.2	258	288	309	6.24e-37	132
k141_152078_14	SARG|gi|507055561|ref|WP_016126482.1|	32.8	256	288	309	8.75e-37	132
k141_152078_14	SARG|gi|488053456|ref|WP_002124853.1|	32.8	256	288	309	8.75e-37	132
k141_152078_14	SARG|gi|507044560|ref|WP_016115614.1|	32.6	258	288	306	1.15e-36	131
k141_152078_14	SARG|gi|500465078|gb|EOP76697.1|	33.2	256	288	306	1.61e-36	131
k141_152078_14	SARG|gi|488067981|ref|WP_002139378.1|	32.8	256	288	309	1.72e-36	131
k141_152078_47	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.9	435	433	444	4.41e-64	211
k141_152078_51	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.4	468	474	481	1.22e-99	306
k141_152078_51	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.8	468	474	451	1.58e-98	302
k141_152078_51	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.3	468	474	451	9.58e-94	290
k141_152078_90	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.4	587	630	655	1.03e-107	338
k141_152078_90	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	1.03e-107	338
k141_152078_90	SARG|gb|AKA86814|ARO:3003746|optrA	35.3	587	630	655	1.03e-107	338
k141_152078_90	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.4	587	630	655	2.04e-107	337
k141_152078_90	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	7.94e-107	335
k141_152078_90	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	7.94e-107	335
k141_152078_90	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	7.94e-107	335
k141_152078_90	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	1.12e-106	335
k141_152078_90	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	1.12e-106	335
k141_152078_90	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	587	630	655	1.57e-106	335
k141_152078_162	SARG|gi|1004359922|gb|AMP42228.1|	26.0	438	607	639	1.08e-28	120
k141_152078_162	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.9	437	607	629	3.28e-27	115
k141_152078_162	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.9	437	607	629	3.28e-27	115
k141_152078_162	ResF|tet(O/W)_4_AM889121_1	25.9	437	607	639	3.40e-27	115
k141_152078_162	ResF|tet(O/W)_5_AM889122_1	25.9	437	607	639	3.40e-27	115
k141_152078_162	SARG|ABN79417	25.6	434	607	639	4.53e-27	115
k141_152078_162	SARG|AAO42740	25.6	434	607	639	4.53e-27	115
k141_152078_162	SARG|AY485126.gene.p01	25.6	434	607	639	4.53e-27	115
k141_152078_162	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.6	434	607	639	4.53e-27	115
k141_152078_162	SARG|ABN80187	25.6	438	607	640	6.06e-27	114
k141_148506_23	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.9	695	660	703	3.31e-84	278
k141_148506_82	SARG|gi|488374619|ref|WP_002444004.1|	23.3	403	449	452	2.29e-24	103
k141_148506_82	SARG|HE999704.1.gene3064.p01	23.3	193	449	241	4.72e-12	64.7
k141_148506_82	SARG|gi|441475675|emb|CCQ25429.1|	23.1	143	449	211	1.54e-07	50.8
k141_167780_19	SARG|gb|APB03222.1|ARO:3003992|rphB	30.2	86	539	884	2.39e-08	55.8
k141_167780_19	NCBI|WP_087348261.1|1|1|rphD|rphD||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphD|AMR|rifamycin	31.3	80	539	872	9.43e-08	53.9
k141_167780_19	NCBI|WP_087347987.1|1|1|rphC|rphC||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphC|AMR|rifamycin	28.8	80	539	868	1.48e-06	50.1
k141_167780_30	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	53.2	158	160	159	2.69e-49	155
k141_167780_43	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.7	529	536	655	3.95e-74	246
k141_167780_43	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.7	529	536	655	5.51e-74	246
k141_167780_43	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	1.50e-73	245
k141_167780_43	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	1.50e-73	245
k141_167780_43	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	1.50e-73	245
k141_167780_43	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	1.50e-73	245
k141_167780_43	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	2.09e-73	244
k141_167780_43	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	2.09e-73	244
k141_167780_43	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	540	536	655	4.06e-73	244
k141_167780_43	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	529	536	655	4.06e-73	244
k141_167780_52	ResF|mre(A)_1_U92073_1	33.2	286	272	310	1.22e-40	141
k141_167780_52	SARG|gb|AAB64408.1|ARO:3007050|mreA	33.2	286	272	311	1.25e-40	141
k141_167780_56	SARG|ZP_02952732	30.2	139	795	652	5.56e-09	58.5
k141_167780_56	SARG|L20800.gene.p01	30.2	139	795	652	5.56e-09	58.5
k141_167780_56	SARG|ZP_02632674	30.2	139	795	660	5.59e-09	58.5
k141_167780_56	SARG|YP_002850805	30.2	139	795	652	1.67e-08	57.0
k141_167780_70	SARG|gi|884875933|emb|CKG93789.1|	33.1	248	282	309	6.20e-34	124
k141_167780_70	SARG|gi|507054395|ref|WP_016125339.1|	32.7	248	282	309	6.20e-34	124
k141_167780_70	SARG|gi|445996724|ref|WP_000074579.1|	32.7	248	282	309	8.67e-34	124
k141_167780_70	SARG|gi|445996722|ref|WP_000074577.1|	32.7	248	282	309	8.67e-34	124
k141_167780_70	SARG|gi|1043490477|ref|WP_065382463.1|	32.3	248	282	309	1.21e-33	123
k141_167780_70	SARG|gi|445996726|ref|WP_000074581.1|	32.3	248	282	309	1.21e-33	123
k141_167780_70	SARG|gi|445996723|ref|WP_000074578.1|	32.3	248	282	309	1.21e-33	123
k141_167780_70	SARG|gi|445996729|ref|WP_000074584.1|	31.5	235	282	309	4.63e-33	122
k141_167780_70	SARG|gi|445996698|ref|WP_000074553.1|	33.3	237	282	309	9.03e-33	121
k141_167780_70	SARG|gi|445996697|ref|WP_000074552.1|	33.2	250	282	309	9.03e-33	121
k141_167780_97	SARG|gi|740856590|ref|WP_038641842.1|	53.0	219	249	648	3.33e-72	231
k141_167780_97	SARG|gi|851928815|ref|WP_048221086.1|	53.0	219	249	648	3.33e-72	231
k141_167780_97	SARG|gi|922960663|ref|WP_053388845.1|	53.0	219	249	648	3.33e-72	231
k141_167780_97	SARG|gi|780033092|ref|WP_045444768.1|	53.0	219	249	648	3.33e-72	231
k141_167780_97	SARG|gi|757799695|ref|WP_043016897.1|	53.0	219	249	648	4.67e-72	231
k141_167780_97	SARG|gi|1045891604|ref|WP_065554100.1|	53.0	219	249	648	4.67e-72	231
k141_167780_97	SARG|gi|507082903|ref|WP_016153652.1|	53.0	219	249	648	4.67e-72	231
k141_167780_97	SARG|gi|507086196|ref|WP_016156937.1|	53.0	219	249	648	4.67e-72	231
k141_167780_97	SARG|gi|835233765|ref|WP_047410073.1|	51.3	234	249	648	6.55e-72	230
k141_167780_97	SARG|gi|491270241|ref|WP_005128370.1|	53.0	219	249	648	9.18e-72	230
k141_167780_134	ResF|penA_1_AF515059_1	24.7	361	463	581	6.60e-14	72.8
k141_167780_141	SARG|gi|851928815|ref|WP_048221086.1|	48.4	219	228	648	6.99e-62	203
k141_167780_141	SARG|gi|780033092|ref|WP_045444768.1|	48.4	219	228	648	6.99e-62	203
k141_167780_141	SARG|YP_001176128	47.3	222	228	646	3.72e-60	198
k141_167780_141	SARG|gi|740856590|ref|WP_038641842.1|	47.9	219	228	648	5.34e-60	198
k141_167780_141	SARG|gi|922960663|ref|WP_053388845.1|	47.9	219	228	648	5.34e-60	198
k141_167780_141	SARG|gi|1032819400|ref|WP_064325534.1|	47.5	219	228	646	7.24e-60	197
k141_167780_141	SARG|gi|757799695|ref|WP_043016897.1|	47.9	219	228	648	7.46e-60	197
k141_167780_141	SARG|gi|1045891604|ref|WP_065554100.1|	47.9	219	228	648	7.46e-60	197
k141_167780_141	SARG|gi|446048013|ref|WP_000125868.1|	47.5	219	228	648	7.46e-60	197
k141_167780_141	SARG|gi|507082903|ref|WP_016153652.1|	47.9	219	228	648	7.46e-60	197
k141_167780_143	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.6	270	331	885	2.78e-19	87.8
k141_167780_143	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.3	243	331	381	6.77e-19	85.5
k141_167780_143	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.3	243	331	381	6.77e-19	85.5
k141_167780_143	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.9	243	331	381	4.23e-18	83.2
k141_167780_143	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.9	243	331	381	4.23e-18	83.2
k141_167780_143	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.1	243	331	381	5.73e-18	82.8
k141_167780_143	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.1	243	331	381	5.73e-18	82.8
k141_167780_143	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.5	243	331	381	7.77e-18	82.4
k141_167780_143	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.5	243	331	381	7.77e-18	82.4
k141_167780_143	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.3	243	331	381	4.79e-17	80.1
k141_167780_144	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	227	225	231	3.88e-51	164
k141_167780_144	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.7	228	225	229	5.18e-51	164
k141_167780_144	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.6	227	225	231	4.39e-50	162
k141_167780_144	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.6	227	225	231	1.76e-49	160
k141_167780_144	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.6	227	225	231	1.76e-49	160
k141_167780_144	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.2	227	225	231	3.51e-49	159
k141_167780_144	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.7	229	225	232	3.61e-49	159
k141_167780_144	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.7	229	225	232	3.61e-49	159
k141_167780_144	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.2	228	225	230	1.22e-46	153
k141_167780_144	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.7	218	225	228	1.84e-45	150
k141_167780_150	SARG|gb|ADZ12699.1|ARO:3005091|RanA	36.0	214	241	258	1.05e-40	139
k141_167780_150	SARG|gi|740610794|ref|WP_038396317.1|	37.3	228	241	648	1.25e-40	146
k141_167780_150	SARG|YP_001571041	36.8	228	241	648	4.48e-40	144
k141_167780_150	SARG|gi|960873409|ref|WP_058345546.1|	36.8	228	241	648	4.48e-40	144
k141_167780_150	SARG|gi|555268367|ref|WP_023249730.1|	36.4	228	241	648	4.17e-39	142
k141_167780_150	SARG|gi|1027935297|ref|WP_063809363.1|	36.4	228	241	648	4.17e-39	142
k141_167780_150	SARG|gi|959866458|ref|WP_058145168.1|	36.4	228	241	648	5.74e-39	141
k141_167780_150	SARG|gi|495067432|ref|WP_007792257.1|	34.6	240	241	647	7.84e-39	141
k141_167780_150	SARG|gi|555246906|ref|WP_023230855.1|	36.4	228	241	648	7.88e-39	141
k141_167780_150	SARG|YP_002044935	36.4	228	241	648	7.88e-39	141
k141_167780_157	SARG|gi|500465078|gb|EOP76697.1|	30.3	218	255	306	1.21e-19	85.1
k141_167780_157	SARG|gi|500448961|gb|EOP61695.1|	30.3	218	255	306	2.31e-19	84.3
k141_167780_157	SARG|YP_001373621	29.2	219	255	318	2.65e-19	84.3
k141_167780_157	SARG|gi|447195835|ref|WP_001273091.1|	29.8	205	255	306	8.30e-19	82.8
k141_167780_157	SARG|gi|507044560|ref|WP_016115614.1|	27.2	213	255	306	1.14e-18	82.4
k141_167780_157	SARG|gi|447195836|ref|WP_001273092.1|	29.3	205	255	306	2.16e-18	81.6
k141_167780_157	SARG|ZP_04081918	29.5	210	255	306	2.98e-18	81.3
k141_167780_157	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	30.2	202	255	550	2.50e-08	53.1
k141_167780_193	SARG|gb|AAK76136.1|ARO:3000025|patB	37.9	530	619	588	4.41e-109	339
k141_167780_193	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.0	535	619	664	6.20e-100	317
k141_167780_193	SARG|gi|664180077|ref|WP_030714054.1|	32.1	613	619	605	4.76e-86	279
k141_167780_193	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.3	598	619	579	9.66e-86	278
k141_167780_193	SARG|gi|764446018|ref|WP_044369325.1|	31.8	613	619	605	1.83e-85	278
k141_167780_193	SARG|gi|695887424|ref|WP_032788534.1|	32.0	613	619	605	2.56e-85	277
k141_167780_193	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.3	600	619	579	2.66e-85	276
k141_167780_193	SARG|gi|497748188|ref|WP_010062372.1|	31.6	613	619	605	3.58e-85	277
k141_167780_193	SARG|gi|663330365|ref|WP_030329892.1|	32.4	593	619	607	5.26e-85	276
k141_167780_193	SARG|gi|664556405|ref|WP_031071225.1|	31.7	609	619	602	6.52e-85	276
k141_167780_194	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.7	567	582	575	1.46e-116	357
k141_167780_194	SARG|gb|AAK76137.1|ARO:3000024|patA	38.2	523	582	564	1.66e-108	335
k141_167780_194	SARG|gi|516795764|ref|WP_018105258.1|	31.1	560	582	601	8.51e-71	238
k141_167780_194	SARG|gi|1045390184|ref|WP_065479071.1|	31.3	560	582	605	9.25e-71	238
k141_167780_194	SARG|gi|664556405|ref|WP_031071225.1|	30.9	560	582	602	2.35e-70	236
k141_167780_194	SARG|gi|928900436|ref|WP_053931243.1|	31.4	560	582	600	4.38e-70	236
k141_167780_194	SARG|gi|664579989|ref|WP_031094015.1|	31.4	560	582	601	4.47e-70	236
k141_167780_194	SARG|gi|505420018|ref|WP_015607120.1|	31.1	560	582	603	4.66e-70	236
k141_167780_194	SARG|gi|947982677|ref|WP_056642336.1|	30.4	560	582	626	7.47e-70	236
k141_167780_194	SARG|gi|639892676|ref|WP_024755698.1|	30.4	560	582	631	8.25e-70	236
k141_167780_196	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	29.1	182	285	243	4.11e-14	69.3
k141_167780_197	SARG|gi|446573718|ref|WP_000651064.1|	32.2	456	464	451	4.25e-78	249
k141_167780_197	SARG|ZP_04679156	32.3	464	464	451	5.98e-78	249
k141_167780_197	SARG|gi|686155635|ref|WP_031787393.1|	32.2	456	464	451	8.41e-78	248
k141_167780_197	SARG|gi|446573715|ref|WP_000651061.1|	31.9	455	464	451	3.29e-77	247
k141_167780_197	SARG|gi|505177635|ref|WP_015364737.1|	31.7	464	464	451	3.29e-77	247
k141_167780_197	SARG|gi|686294396|ref|WP_031862836.1|	31.9	455	464	451	4.63e-77	246
k141_167780_197	SARG|gi|686390606|ref|WP_031905637.1|	31.9	455	464	451	4.63e-77	246
k141_167780_197	SARG|Q2G140	31.9	455	464	451	4.63e-77	246
k141_167780_197	SARG|gi|763462741|ref|WP_044292157.1|	31.6	455	464	451	6.51e-77	246
k141_167780_197	SARG|gi|727749287|ref|WP_033861814.1|	31.9	455	464	451	9.16e-77	246
k141_167780_254	SARG|gb|CAE00499.1|ARO:3003835|cdeA	23.0	434	453	441	1.58e-21	95.5
k141_167780_263	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	58.2	239	355	392	8.02e-89	271
k141_167780_263	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	55.5	238	355	388	7.23e-83	256
k141_167780_263	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	55.5	238	355	388	7.23e-83	256
k141_167780_263	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	54.6	238	355	386	5.42e-82	253
k141_167780_263	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	54.6	238	355	386	5.42e-82	253
k141_167780_263	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	54.6	238	355	386	3.05e-81	251
k141_167780_263	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	54.6	238	355	386	3.05e-81	251
k141_167780_263	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	54.2	238	355	384	1.14e-80	250
k141_167780_263	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	54.2	238	355	384	1.14e-80	250
k141_167780_263	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	54.6	238	355	382	1.52e-80	249
k141_167780_264	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	64.9	231	232	235	1.96e-113	323
k141_167780_264	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	64.5	231	232	233	8.65e-112	319
k141_167780_264	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	66.1	230	232	232	2.27e-109	313
k141_167780_264	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	66.5	230	232	232	9.22e-109	311
k141_167780_264	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	66.1	230	232	232	3.74e-108	310
k141_167780_264	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	65.7	230	232	232	1.07e-107	308
k141_167780_264	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	65.7	230	232	232	1.52e-107	308
k141_167780_264	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	62.6	230	232	232	8.75e-107	306
k141_167780_264	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	62.6	230	232	232	8.75e-107	306
k141_167780_264	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	65.8	231	232	232	3.55e-106	305
k141_167780_276	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	31.2	253	792	365	1.27e-30	123
k141_167780_276	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.3	249	792	370	4.63e-30	121
k141_167780_276	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.3	283	792	367	2.09e-25	107
k141_167780_276	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.1	287	792	381	9.03e-24	103
k141_167780_276	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.1	287	792	381	9.03e-24	103
k141_167780_276	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.6	282	792	368	1.83e-23	102
k141_167780_276	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.8	259	792	380	2.91e-23	101
k141_167780_276	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.8	259	792	380	2.91e-23	101
k141_167780_276	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.8	290	792	381	1.01e-21	97.1
k141_167780_276	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.8	290	792	381	1.01e-21	97.1
k141_167780_277	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.4	128	125	232	4.80e-28	101
k141_167780_277	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.4	128	125	232	4.80e-28	101
k141_167780_277	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.6	125	125	231	9.33e-28	100
k141_167780_277	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.4	125	125	231	4.04e-26	96.7
k141_167780_277	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	125	125	231	4.04e-26	96.7
k141_167780_277	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.8	125	125	231	4.42e-25	94.0
k141_167780_277	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.8	125	125	231	4.42e-25	94.0
k141_167780_277	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.7	126	125	231	8.74e-25	93.2
k141_167780_277	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.7	126	125	231	8.74e-25	93.2
k141_167780_277	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.7	126	125	231	8.74e-25	93.2
k141_8423_51	NCBI|CAJ68095.1|1|1|vanZ1|vanZ1|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ1|AMR|glycopeptide	27.7	141	190	169	8.39e-09	51.6
k141_8423_51	SARG|CAB61225	36.0	86	190	161	1.85e-07	47.8
k141_8423_51	SARG|ACP19239	34.1	91	190	161	4.81e-07	46.6
k141_8423_51	megares|MEG_7452|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.1	91	190	161	4.81e-07	46.6
k141_8423_69	SARG|CAP74085	27.0	111	202	210	1.26e-06	46.2
k141_8423_72	SARG|Q02652	22.1	666	684	639	2.57e-24	107
k141_8423_92	SARG|gi|487410704|ref|WP_001678420.1|	32.2	425	418	648	1.39e-46	168
k141_8423_92	SARG|gi|928831144|ref|WP_053888514.1|	32.0	425	418	648	1.91e-46	168
k141_8423_92	SARG|gi|486228670|ref|WP_001558901.1|	32.0	425	418	648	3.62e-46	167
k141_8423_92	SARG|gi|766961649|ref|WP_044860626.1|	32.0	425	418	648	3.62e-46	167
k141_8423_92	SARG|gi|693106883|ref|WP_032260279.1|	32.2	425	418	648	4.98e-46	167
k141_8423_92	SARG|gi|323172150|gb|EFZ57788.1|	32.0	425	418	648	4.98e-46	167
k141_8423_92	SARG|gi|485866062|ref|WP_001464282.1|	32.0	425	418	648	4.98e-46	167
k141_8423_92	SARG|gi|971845730|ref|WP_058914924.1|	32.2	425	418	648	4.98e-46	167
k141_8423_92	SARG|gi|647323678|ref|WP_025760497.1|	32.0	425	418	648	4.98e-46	167
k141_8423_92	SARG|gi|895859668|ref|WP_048970096.1|	32.2	425	418	648	4.98e-46	167
k141_8423_111	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.5	850	803	1024	7.44e-35	142
k141_8423_111	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.5	850	803	1024	7.44e-35	142
k141_8423_111	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.5	850	803	1024	7.44e-35	142
k141_8423_111	SARG|gb|CAA53189|ARO:3000521|mupA	23.5	850	803	1024	7.44e-35	142
k141_8423_111	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.1	870	803	1033	3.07e-27	117
k141_8423_111	SARG|gb|AEY83581|ARO:3000510|mupB	23.1	870	803	1033	3.07e-27	117
k141_8423_111	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	886	803	1107	2.79e-20	95.5
k141_8423_111	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	886	803	1107	2.79e-20	95.5
k141_8423_151	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	37.9	116	207	342	3.80e-18	80.1
k141_8423_151	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	41.5	94	207	313	4.90e-16	73.9
k141_8423_151	SARG|AB636283.1.gene1.p01	31.3	134	207	280	4.92e-12	62.4
k141_8423_151	SARG|AJ250876.1.gene1.p01	27.3	187	207	316	3.84e-11	60.1
k141_8423_151	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	33.3	99	207	310	2.36e-10	57.8
k141_8423_151	SARG|gi|499222460|ref|WP_010920000.1|	36.0	89	207	289	7.37e-10	56.2
k141_8423_151	SARG|gi|1028105810|ref|WP_063860835.1|	36.0	89	207	289	1.00e-09	55.8
k141_8423_151	SARG|gb|WP_012145975.1|ARO:3006996|SPR-1	33.3	93	207	298	1.41e-09	55.5
k141_8423_151	NCBI|WP_304486996.1|1|1|blaL1|blaL1|hydrolase|2|||L1_family_subclass_B3_metallo-beta-lactamase|AMR|beta-lactam	35.5	93	207	290	1.85e-09	55.1
k141_8423_151	SARG|AJ308331.1.gene1.p01	34.8	89	207	289	2.51e-09	54.7
k141_114871_5	SARG|CAA37477	47.2	142	608	663	1.56e-30	125
k141_114871_5	SARG|AJ514254.gene.p01	28.2	380	608	640	6.12e-29	120
k141_114871_5	SARG|AAV80410	28.4	335	608	651	1.52e-28	119
k141_114871_5	SARG|L42544.gene.p01	45.1	142	608	651	4.79e-28	118
k141_114871_5	SARG|ABB70054	43.2	132	608	639	1.01e-23	104
k141_114871_5	SARG|ABI81214	43.2	132	608	639	1.01e-23	104
k141_114871_5	SARG|BAB71968	43.2	132	608	639	1.01e-23	104
k141_114871_5	SARG|YP_002738300	43.2	132	608	639	1.01e-23	104
k141_114871_5	SARG|Q02652	41.1	141	608	639	1.01e-23	104
k141_114871_5	SARG|X04388.gene.p01	42.4	132	608	639	1.34e-23	104
k141_114871_13	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	38.2	199	323	337	1.11e-29	114
k141_114871_13	SARG|CAB61228	32.8	262	323	322	8.34e-28	109
k141_114871_13	SARG|YP_002333394	33.0	261	323	323	2.26e-27	108
k141_114871_13	SARG|AF310956.2.gene5.p01	33.0	261	323	323	3.13e-27	107
k141_114871_13	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	33.0	261	323	323	3.13e-27	107
k141_114871_13	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	30.9	262	323	343	5.96e-27	107
k141_114871_13	SARG|gb|AAB05626.1|ARO:3002943|vanHB	33.3	252	323	323	5.99e-27	107
k141_114871_13	SARG|gi|498515089|ref|WP_010815296.1|	33.3	252	323	323	8.30e-27	106
k141_114871_13	SARG|Q47748	33.3	252	323	323	8.30e-27	106
k141_114871_13	SARG|gi|985522333|ref|WP_060811962.1|	33.3	252	323	323	8.30e-27	106
k141_31770_4	SARG|gi|500194536|ref|WP_011867743.1|	38.5	221	300	306	2.81e-47	159
k141_31770_4	SARG|gi|447195835|ref|WP_001273091.1|	40.8	211	300	306	2.81e-47	159
k141_31770_4	SARG|gi|500465078|gb|EOP76697.1|	39.4	221	300	306	7.82e-47	158
k141_31770_4	SARG|gi|500448961|gb|EOP61695.1|	39.4	221	300	306	1.10e-46	158
k141_31770_4	SARG|gi|542061059|gb|ERI11611.1|	34.0	306	300	316	1.41e-46	158
k141_31770_4	SARG|P42332	40.3	211	300	306	1.55e-46	157
k141_31770_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	40.3	211	300	306	1.55e-46	157
k141_31770_4	SARG|gi|510143239|gb|AGN36970.1|	40.3	211	300	313	1.84e-46	157
k141_31770_4	SARG|ABB80128	40.3	211	300	306	2.17e-46	157
k141_31770_4	SARG|gi|445996719|ref|WP_000074574.1|	35.6	270	300	309	6.52e-46	156
k141_126584_6	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	29.1	213	387	343	6.93e-19	85.9
k141_126584_6	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	29.1	213	387	348	7.29e-19	85.9
k141_126584_6	SARG|KF478993.1.gene2.p01	29.1	213	387	350	3.78e-17	80.9
k141_126584_6	SARG|AAY52004	29.6	223	387	322	5.30e-17	80.1
k141_126584_6	SARG|gi|740152780|ref|WP_037997109.1|	28.9	201	387	322	2.40e-16	78.2
k141_126584_6	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	28.7	216	387	337	2.76e-16	78.2
k141_126584_6	SARG|gi|749574782|ref|WP_040203616.1|	28.6	220	387	323	1.09e-15	76.3
k141_126584_12	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.9	795	932	1024	4.02e-121	392
k141_126584_12	SARG|gb|CAA53189|ARO:3000521|mupA	31.9	795	932	1024	4.02e-121	392
k141_126584_12	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	31.9	795	932	1024	5.60e-121	392
k141_126584_12	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.9	795	932	1024	5.60e-121	392
k141_126584_12	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	30.3	780	932	1033	4.95e-109	360
k141_126584_12	SARG|gb|AEY83581|ARO:3000510|mupB	30.3	780	932	1033	4.95e-109	360
k141_126584_52	SARG|AAN28721	44.8	96	380	108	2.90e-17	75.9
k141_142166_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.0	523	562	575	2.15e-36	142
k141_142166_8	SARG|gb|AAK76136.1|ARO:3000025|patB	27.5	403	562	588	2.77e-32	130
k141_142166_8	SARG|gb|AAV85982.1|ARO:3000535|macB	35.1	225	562	644	2.13e-19	90.9
k141_142166_8	SARG|gi|488243106|ref|WP_002314314.1|	27.7	213	562	492	9.51e-11	63.2
k141_142166_8	SARG|U82085.gene.p01	26.4	212	562	552	9.76e-10	60.1
k141_142166_8	SARG|gb|AVI44920.1|ARO:3004470|poxtA	28.0	200	562	542	8.91e-09	57.0
k141_142166_8	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	28.0	200	562	544	8.94e-09	57.0
k141_142166_8	ResF|poxtA-Ef_1_WP094899500.1_1	26.0	215	562	538	1.55e-08	56.2
k141_142166_8	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.0	215	562	543	1.56e-08	56.2
k141_142166_8	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.0	215	562	543	1.56e-08	56.2
k141_142166_19	SARG|gi|488067981|ref|WP_002139378.1|	31.5	235	278	309	1.25e-29	112
k141_142166_19	SARG|gi|507050365|ref|WP_016121371.1|	31.1	235	278	309	1.25e-29	112
k141_142166_19	SARG|gi|487936534|ref|WP_002010000.1|	31.5	235	278	309	1.25e-29	112
k141_142166_19	SARG|gi|488120365|ref|WP_002191762.1|	30.6	235	278	309	1.74e-29	112
k141_142166_19	SARG|gi|445996729|ref|WP_000074584.1|	31.5	235	278	309	2.43e-29	112
k141_142166_19	SARG|gi|446110087|ref|WP_000187942.1|	31.5	235	278	309	2.43e-29	112
k141_142166_19	SARG|gi|488130770|ref|WP_002201978.1|	31.1	235	278	309	3.38e-29	111
k141_142166_19	SARG|gi|488042066|ref|WP_002113463.1|	31.1	235	278	309	3.38e-29	111
k141_142166_19	SARG|gi|447057509|ref|WP_001134765.1|	29.8	255	278	309	3.38e-29	111
k141_142166_19	SARG|gi|488068784|ref|WP_002140181.1|	31.1	235	278	309	3.38e-29	111
k141_116410_14	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.5	218	249	578	1.30e-18	83.6
k141_116410_27	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.6	220	227	219	1.21e-44	147
k141_116410_27	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	234	227	231	2.39e-44	147
k141_116410_27	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.3	228	227	231	3.38e-44	147
k141_116410_27	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.3	228	227	231	3.38e-44	147
k141_116410_27	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.4	227	227	232	1.92e-40	137
k141_116410_27	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	227	227	231	1.04e-39	135
k141_116410_27	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.7	230	227	252	1.28e-39	135
k141_116410_27	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.7	177	227	229	1.05e-35	125
k141_116410_27	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	33.5	218	227	225	2.65e-35	124
k141_116410_27	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.6	221	227	235	1.14e-32	117
k141_116410_28	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.6	304	441	451	5.82e-31	122
k141_116410_28	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.6	248	441	467	1.29e-24	104
k141_116410_28	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.6	245	441	392	9.99e-24	101
k141_116410_28	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	237	441	381	1.15e-21	95.1
k141_116410_28	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.0	237	441	381	1.15e-21	95.1
k141_116410_28	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	237	441	381	1.05e-19	89.4
k141_116410_28	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	237	441	381	1.05e-19	89.4
k141_116410_28	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.3	237	441	381	2.58e-19	88.2
k141_116410_28	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.3	237	441	381	2.58e-19	88.2
k141_116410_28	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.6	211	441	370	1.32e-13	70.9
k141_165084_69	SARG|gb|APB03216.1|ARO:3003982|LlmA	52.8	288	292	287	6.62e-111	321
k141_165084_70	SARG|gi|671541568|ref|WP_031525212.1|	35.0	226	284	648	2.09e-28	113
k141_165084_70	SARG|gi|1035670474|ref|WP_064517458.1|	34.5	226	284	648	2.79e-26	107
k141_165084_70	SARG|gi|1035717981|ref|WP_064557480.1|	34.5	226	284	648	2.79e-26	107
k141_165084_70	SARG|gi|736472622|ref|WP_034494292.1|	34.5	226	284	648	5.12e-26	106
k141_165084_70	SARG|gi|498115003|ref|WP_010429159.1|	32.2	233	284	646	5.83e-25	103
k141_165084_70	SARG|gi|983405167|ref|WP_060572706.1|	31.8	233	284	646	1.96e-24	101
k141_165084_70	SARG|gi|754493745|ref|WP_041910640.1|	31.8	233	284	646	3.60e-24	100
k141_165084_70	SARG|gi|779861244|ref|WP_045352062.1|	31.6	234	284	646	3.60e-24	100
k141_165084_70	SARG|gi|895872463|ref|WP_048979698.1|	31.8	233	284	646	3.60e-24	100
k141_165084_70	SARG|gi|695748190|ref|WP_032674455.1|	31.8	233	284	646	4.88e-24	100
k141_165084_71	SARG|gb|AAV85982.1|ARO:3000535|macB	30.6	229	290	644	7.01e-22	94.4
k141_165084_71	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	25.1	247	290	578	4.45e-20	89.0
k141_165084_71	SARG|gb|AAK76137.1|ARO:3000024|patA	28.0	225	290	564	1.08e-19	87.8
k141_165084_71	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.5	239	290	579	4.92e-19	85.9
k141_165084_71	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	26.0	200	290	293	9.75e-19	83.2
k141_165084_71	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.4	236	290	579	1.21e-18	84.7
k141_165084_71	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.8	236	290	664	1.75e-18	84.3
k141_165084_71	SARG|gi|556478535|ref|WP_023330119.1|	28.9	204	290	646	5.72e-18	82.8
k141_165084_71	SARG|gi|921979807|ref|WP_053271336.1|	28.4	208	290	648	8.40e-17	79.3
k141_165084_71	SARG|gi|514904648|ref|WP_016630030.1|	28.2	195	290	498	1.95e-09	57.0
k141_165084_82	SARG|gi|657888313|ref|WP_029592374.1|	52.9	34	50	648	9.42e-07	42.0
k141_165084_82	SARG|gi|639225329|ref|WP_024561799.1|	52.9	34	50	648	9.42e-07	42.0
k141_165084_82	SARG|gi|639218559|ref|WP_024556062.1|	52.9	34	50	648	9.42e-07	42.0
k141_165084_82	SARG|gi|654544841|ref|WP_028012549.1|	52.9	34	50	646	1.29e-06	41.6
k141_165084_82	SARG|gi|754493745|ref|WP_041910640.1|	52.9	34	50	646	1.29e-06	41.6
k141_165084_82	SARG|gi|782756348|ref|WP_045630015.1|	52.9	34	50	646	1.29e-06	41.6
k141_165084_82	SARG|gi|896106549|ref|WP_049136608.1|	52.9	34	50	646	1.29e-06	41.6
k141_165084_82	SARG|gi|983405167|ref|WP_060572706.1|	52.9	34	50	646	1.29e-06	41.6
k141_165084_82	SARG|gi|495736522|ref|WP_008461101.1|	50.0	34	50	648	3.32e-06	40.4
k141_165084_82	SARG|gi|746253210|ref|WP_039301529.1|	50.0	34	50	648	3.32e-06	40.4
k141_165084_83	SARG|Q83LR7	39.6	197	198	648	3.49e-44	154
k141_165084_83	SARG|gi|647325472|ref|WP_025760953.1|	39.6	197	198	648	3.49e-44	154
k141_165084_83	SARG|gi|647323678|ref|WP_025760497.1|	39.6	197	198	648	3.49e-44	154
k141_165084_83	SARG|gi|446110305|ref|WP_000188160.1|	39.1	197	198	648	1.27e-43	152
k141_165084_83	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.8	184	198	255	1.39e-43	145
k141_165084_83	SARG|gi|1035686596|ref|WP_064530178.1|	40.6	187	198	648	2.43e-43	152
k141_165084_83	SARG|gi|742907943|ref|WP_039020462.1|	38.6	197	198	648	4.63e-43	151
k141_165084_83	SARG|gi|446110309|ref|WP_000188164.1|	38.6	197	198	648	4.63e-43	151
k141_165084_83	SARG|gi|446110310|ref|WP_000188165.1|	38.6	197	198	648	4.63e-43	151
k141_165084_83	SARG|gi|486326725|ref|WP_001583395.1|	38.6	197	198	648	6.39e-43	150
k141_165084_86	SARG|gi|500448961|gb|EOP61695.1|	28.9	211	267	306	1.18e-20	88.2
k141_165084_86	SARG|gi|500465078|gb|EOP76697.1|	28.9	211	267	306	3.10e-20	87.0
k141_165084_86	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.1	236	267	255	1.42e-19	84.3
k141_165084_86	SARG|ZP_04081918	29.2	192	267	306	7.62e-19	83.2
k141_165084_86	SARG|gi|500194536|ref|WP_011867743.1|	28.0	211	267	306	1.98e-18	82.0
k141_165084_86	SARG|gi|447195835|ref|WP_001273091.1|	28.6	192	267	306	3.74e-18	81.3
k141_165084_86	SARG|gi|447195836|ref|WP_001273092.1|	28.6	192	267	306	5.13e-18	80.9
k141_165084_86	SARG|gi|803568669|ref|WP_046077412.1|	31.2	234	267	648	7.41e-17	79.0
k141_165084_86	SARG|gi|446110352|ref|WP_000188207.1|	31.2	234	267	648	7.41e-17	79.0
k141_165084_86	SARG|YP_002382193	31.2	234	267	648	7.41e-17	79.0
k141_165084_119	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.7	1224	1255	1162	0.0	1220
k141_165084_119	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	52.5	1231	1255	1186	0.0	1169
k141_165084_119	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	52.5	1231	1255	1186	0.0	1169
k141_165084_123	SARG|L42544.gene.p01	27.4	680	703	651	4.42e-79	264
k141_165084_123	SARG|AAV80410	27.2	680	703	651	6.22e-78	261
k141_165084_123	SARG|NP_348076	26.4	677	703	652	2.39e-74	251
k141_165084_123	SARG|YP_002850805	26.2	684	703	652	8.62e-71	242
k141_165084_123	SARG|ZP_02952732	26.0	684	703	652	1.17e-69	239
k141_165084_123	SARG|ZP_02632674	26.0	684	703	660	1.37e-69	239
k141_165084_123	SARG|L20800.gene.p01	26.0	684	703	652	3.12e-69	238
k141_165084_123	SARG|CAA37477	26.3	691	703	663	1.53e-51	189
k141_165084_123	SARG|AAO42740	28.9	485	703	639	9.81e-51	186
k141_165084_123	SARG|AY485126.gene.p01	28.9	485	703	639	9.81e-51	186
k141_165084_124	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.4	131	398	639	1.10e-15	77.8
k141_165084_148	SARG|M80346.gene.p01	27.6	254	379	551	8.01e-17	80.9
k141_165084_148	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	27.6	254	379	551	8.01e-17	80.9
k141_165084_148	SARG|X63451.gene.p01	27.0	259	379	550	1.95e-15	76.6
k141_165084_148	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	27.0	259	379	550	1.95e-15	76.6
k141_165084_148	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.9	224	379	550	1.95e-12	67.4
k141_165084_189	SARG|gi|1035706844|ref|WP_064548272.1|	33.7	89	941	648	1.08e-07	54.7
k141_165084_192	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.2	229	238	232	7.01e-47	154
k141_165084_192	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.2	229	238	232	7.01e-47	154
k141_165084_192	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.4	230	238	231	1.36e-46	153
k141_165084_192	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.7	230	238	228	3.52e-46	152
k141_165084_192	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.2	227	238	232	1.57e-45	150
k141_165084_192	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.3	233	238	239	3.80e-45	150
k141_165084_192	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.9	236	238	235	9.57e-45	149
k141_165084_192	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.5	230	238	231	1.71e-44	148
k141_165084_192	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.3	238	238	232	1.75e-44	148
k141_165084_192	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	234	238	231	3.40e-44	147
k141_165084_193	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.9	215	514	359	2.36e-19	88.6
k141_165084_215	SARG|gi|446573707|ref|WP_000651053.1|	23.1	385	461	451	7.67e-25	105
k141_165084_215	SARG|gi|763462741|ref|WP_044292157.1|	23.8	386	461	451	7.67e-25	105
k141_165084_215	SARG|gi|446573715|ref|WP_000651061.1|	23.8	386	461	451	7.67e-25	105
k141_165084_215	SARG|gi|446573718|ref|WP_000651064.1|	22.9	393	461	451	7.67e-25	105
k141_165084_215	SARG|gi|565830932|ref|WP_023914633.1|	23.2	388	461	451	1.04e-24	105
k141_165084_215	SARG|gi|686334333|ref|WP_031881350.1|	23.8	386	461	451	1.04e-24	105
k141_165084_215	SARG|gi|537465183|ref|WP_020976941.1|	22.9	385	461	451	1.04e-24	105
k141_165084_215	SARG|YP_302230	20.3	453	461	451	1.04e-24	105
k141_165084_215	SARG|gi|686294396|ref|WP_031862836.1|	23.8	386	461	451	1.04e-24	105
k141_165084_215	SARG|gi|686390606|ref|WP_031905637.1|	23.8	386	461	451	1.04e-24	105
k141_165084_216	SARG|gi|313638554|gb|EFS03703.1|	24.2	443	446	453	1.84e-31	124
k141_165084_216	SARG|gi|313614636|gb|EFR88215.1|	23.6	424	446	453	3.43e-31	123
k141_165084_216	SARG|HE999704.1.gene1126.p01	22.5	293	446	337	2.31e-19	87.8
k141_165084_216	SARG|gi|441473784|emb|CCQ23538.1|	22.5	293	446	336	6.23e-18	83.6
k141_165084_216	SARG|gi|313619623|gb|EFR91268.1|	25.8	221	446	237	1.11e-16	78.2
k141_165084_216	SARG|gi|313609598|gb|EFR85124.1|	25.1	199	446	226	3.00e-14	70.9
k141_165084_224	SARG|gi|488374619|ref|WP_002444004.1|	28.9	426	457	452	2.81e-56	192
k141_165084_224	SARG|gi|505177635|ref|WP_015364737.1|	28.6	426	457	451	3.99e-55	189
k141_165084_224	SARG|gi|1006223553|ref|WP_061745579.1|	28.6	427	457	451	3.04e-53	184
k141_165084_224	SARG|ZP_04679156	28.4	426	457	451	4.24e-53	183
k141_165084_224	SARG|gi|686309068|ref|WP_031870147.1|	28.6	427	457	451	2.24e-52	181
k141_165084_224	SARG|YP_302230	29.6	412	457	451	3.12e-52	181
k141_165084_224	SARG|gi|487138435|ref|WP_001629863.1|	28.6	427	457	451	4.35e-52	181
k141_165084_224	SARG|gi|565830932|ref|WP_023914633.1|	28.3	427	457	451	6.07e-52	180
k141_165084_224	SARG|gi|686408548|ref|WP_031913080.1|	28.1	427	457	451	6.07e-52	180
k141_165084_224	SARG|ZP_03986195	28.1	427	457	451	6.07e-52	180
k141_165084_249	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.1	545	571	575	2.19e-112	345
k141_165084_249	SARG|gb|AAK76137.1|ARO:3000024|patA	31.7	508	571	564	5.67e-79	258
k141_165084_249	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.0	485	571	582	3.21e-55	195
k141_165084_249	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.8	494	571	574	9.87e-54	191
k141_165084_249	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.2	391	571	579	3.36e-50	181
k141_165084_249	SARG|gi|664042835|ref|WP_030582300.1|	41.8	225	571	604	6.27e-49	178
k141_165084_249	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.0	496	571	664	1.35e-48	178
k141_165084_249	SARG|gi|917203192|ref|WP_051809904.1|	41.6	226	571	620	1.47e-48	177
k141_165084_249	SARG|gb|AAK76136.1|ARO:3000025|patB	27.8	486	571	588	2.45e-48	176
k141_165084_249	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.2	391	571	579	2.95e-48	176
k141_165084_250	SARG|gb|AAK76136.1|ARO:3000025|patB	35.3	533	584	588	5.34e-99	311
k141_165084_250	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.6	497	584	664	1.18e-95	305
k141_165084_250	SARG|gb|CDO61516.1|ARO:3003949|efrB	46.9	309	584	362	3.74e-91	284
k141_165084_250	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.1	576	584	579	9.67e-82	266
k141_165084_250	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.0	535	584	582	2.04e-81	265
k141_165084_250	SARG|gi|772774655|ref|WP_045322518.1|	30.1	539	584	620	3.70e-80	263
k141_165084_250	SARG|gi|917203192|ref|WP_051809904.1|	29.9	539	584	620	1.01e-79	262
k141_165084_250	SARG|gi|496018010|ref|WP_008742581.1|	29.9	539	584	623	1.51e-79	261
k141_165084_250	SARG|gi|799286378|ref|WP_045936958.1|	29.7	539	584	620	1.97e-79	261
k141_165084_250	SARG|gi|917127754|ref|WP_051734466.1|	29.7	539	584	620	1.97e-79	261
k141_165084_281	SARG|B1LLK9	28.6	311	309	660	3.32e-33	127
k141_165084_281	SARG|gi|446783041|ref|WP_000860297.1|	29.3	276	309	660	1.14e-32	126
k141_165084_281	SARG|gi|550713000|ref|WP_022645909.1|	29.3	276	309	660	1.56e-32	125
k141_165084_281	SARG|gi|446783044|ref|WP_000860300.1|	29.0	276	309	660	7.28e-32	124
k141_165084_281	SARG|gi|486408016|ref|WP_001609182.1|	29.0	276	309	660	7.28e-32	124
k141_165084_281	SARG|gi|555592548|ref|WP_023278441.1|	29.3	276	309	660	3.39e-31	122
k141_165084_281	SARG|gi|754613472|ref|WP_042002901.1|	29.3	276	309	660	4.61e-31	121
k141_165084_281	SARG|gi|486157188|ref|WP_001520903.1|	29.3	276	309	660	4.61e-31	121
k141_165084_281	SARG|gi|692997842|ref|WP_032184680.1|	29.3	276	309	660	6.27e-31	121
k141_165084_281	SARG|gi|735685540|ref|WP_034173220.1|	29.3	276	309	660	6.27e-31	121
k141_165084_284	SARG|gb|ACX65640.1|ARO:3003907|cipA	36.7	335	345	346	5.46e-62	200
k141_165084_284	SARG|CP001581.1.gene3143.p01	34.8	333	345	344	4.89e-59	192
k141_165084_284	SARG|gb|CAL84423.1|ARO:3004146|cfrC	34.5	333	345	344	5.87e-57	187
k141_165084_284	SARG|AXY65402.1	36.8	348	345	357	1.93e-54	181
k141_165084_284	SARG|gb|BAD63613.1|ARO:3002816|clbC	33.4	347	345	350	6.83e-53	177
k141_165084_286	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.4	655	687	718	3.44e-93	303
k141_165084_319	SARG|gi|749574782|ref|WP_040203616.1|	35.5	259	321	323	4.17e-33	123
k141_165084_319	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	35.0	243	321	337	2.07e-31	119
k141_165084_319	SARG|gi|740152780|ref|WP_037997109.1|	33.2	253	321	322	4.21e-31	118
k141_165084_319	SARG|AF155139.2.gene6.p01	35.0	254	321	322	3.04e-30	115
k141_165084_319	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	29.2	284	321	314	3.64e-30	115
k141_165084_319	SARG|DQ018711.1.gene4.p01	31.7	271	321	322	8.16e-30	114
k141_165084_319	SARG|gi|746609237|ref|WP_039635344.1|	34.3	254	321	322	3.03e-29	113
k141_165084_319	SARG|gi|737310392|ref|WP_035293250.1|	31.7	271	321	323	4.29e-29	112
k141_165084_319	SARG|FJ349556.1.gene5.p01	33.1	263	321	326	4.52e-29	112
k141_165084_333	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	28.4	222	325	346	1.31e-12	66.6
k141_165084_354	SARG|gb|AAV85982.1|ARO:3000535|macB	33.6	250	276	644	2.99e-24	100
k141_165084_354	SARG|gi|639216333|ref|WP_024554080.1|	29.7	239	276	648	3.19e-21	92.0
k141_165084_354	SARG|gi|657888313|ref|WP_029592374.1|	30.5	236	276	648	3.57e-20	89.0
k141_165084_354	SARG|gi|896325272|ref|WP_049294291.1|	28.9	239	276	648	1.19e-19	87.4
k141_165084_354	SARG|gi|981224618|ref|WP_059445588.1|	29.5	227	276	646	1.61e-19	87.0
k141_165084_354	SARG|gi|836585048|ref|WP_047742322.1|	29.5	227	276	646	1.61e-19	87.0
k141_165084_354	SARG|gi|779852631|ref|WP_045348970.1|	29.7	229	276	646	2.17e-19	86.7
k141_165084_354	SARG|gi|836580371|ref|WP_047737758.1|	29.7	229	276	646	2.17e-19	86.7
k141_165084_354	SARG|gi|798928072|ref|WP_045906664.1|	29.7	229	276	646	2.17e-19	86.7
k141_165084_354	SARG|gi|746222054|ref|WP_039271209.1|	29.7	229	276	646	2.17e-19	86.7
k141_165084_355	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.3	217	281	258	1.05e-25	101
k141_165084_355	SARG|gi|498115003|ref|WP_010429159.1|	29.2	233	281	646	3.37e-24	100
k141_165084_355	SARG|gi|983405167|ref|WP_060572706.1|	29.2	233	281	646	1.53e-23	99.0
k141_165084_355	SARG|gi|695731408|ref|WP_032657917.1|	28.8	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|896088003|ref|WP_049126277.1|	28.8	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|779852631|ref|WP_045348970.1|	28.3	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|836580371|ref|WP_047737758.1|	28.3	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|1028180030|ref|WP_063927084.1|	28.8	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|896106549|ref|WP_049136608.1|	29.2	233	281	646	3.81e-23	97.8
k141_165084_355	SARG|gi|798928072|ref|WP_045906664.1|	28.3	233	281	646	3.81e-23	97.8
k141_169987_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	51.4	107	110	239	9.54e-37	123
k141_169987_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	48.1	106	110	232	3.20e-36	122
k141_169987_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	48.1	106	110	232	3.20e-36	122
k141_169987_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	51.4	105	110	231	4.41e-36	121
k141_169987_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	50.5	107	110	233	6.55e-36	121
k141_169987_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	49.1	106	110	232	5.09e-35	119
k141_169987_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	47.7	107	110	235	2.44e-33	114
k141_169987_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.4	108	110	229	1.19e-32	112
k141_169987_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	44.4	108	110	230	1.72e-32	112
k141_169987_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	48.6	107	110	232	2.55e-32	112
k141_169987_4	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.1	306	517	381	1.68e-35	135
k141_169987_4	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.1	306	517	381	1.68e-35	135
k141_169987_4	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.3	246	517	381	1.78e-32	127
k141_169987_4	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.3	246	517	381	1.78e-32	127
k141_169987_4	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.3	244	517	381	2.44e-32	126
k141_169987_4	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.3	244	517	381	2.44e-32	126
k141_169987_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	283	517	381	8.56e-32	125
k141_169987_4	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	283	517	381	8.56e-32	125
k141_169987_4	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.7	290	517	367	1.73e-31	124
k141_169987_4	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.3	283	517	381	7.66e-31	122
k141_169987_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.8	228	229	229	3.30e-61	190
k141_169987_5	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.4	227	229	231	7.03e-61	189
k141_169987_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.8	229	229	232	4.12e-60	187
k141_169987_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.8	229	229	232	4.12e-60	187
k141_169987_5	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.9	228	229	231	8.01e-60	187
k141_169987_5	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.0	227	229	231	8.01e-60	187
k141_169987_5	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.9	228	229	231	8.01e-60	187
k141_169987_5	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	227	229	231	1.13e-59	186
k141_169987_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.4	231	229	219	1.45e-57	181
k141_169987_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.7	228	229	233	1.56e-57	181
k141_14609_22	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	24.5	515	489	568	6.44e-18	85.5
k141_14609_22	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.0	521	489	550	2.57e-17	83.6
k141_14609_22	SARG|gi|516510995|ref|WP_017899433.1|	27.4	201	489	646	3.90e-16	80.1
k141_14609_22	SARG|gi|1035706844|ref|WP_064548272.1|	31.2	231	489	648	3.91e-16	80.1
k141_14609_22	SARG|gi|736472622|ref|WP_034494292.1|	30.3	231	489	648	5.18e-16	79.7
k141_14609_22	SARG|gi|647265102|ref|WP_025712979.1|	26.9	201	489	646	9.10e-16	79.0
k141_14609_22	SARG|gi|556476567|ref|WP_023328168.1|	27.0	196	489	641	1.20e-15	78.6
k141_14609_22	SARG|gi|1031822889|ref|WP_064150402.1|	26.9	201	489	646	1.60e-15	78.2
k141_14609_22	SARG|gi|490306253|ref|WP_004201358.1|	26.9	201	489	646	1.60e-15	78.2
k141_14609_22	SARG|gi|950164608|ref|WP_057214157.1|	26.9	201	489	646	1.60e-15	78.2
k141_14609_35	SARG|gi|974672242|ref|WP_059256507.1|	38.4	224	252	648	6.75e-41	147
k141_14609_35	SARG|gi|974641719|ref|WP_059227752.1|	38.4	224	252	648	6.75e-41	147
k141_14609_35	SARG|gi|446110299|ref|WP_000188154.1|	38.4	224	252	648	6.75e-41	147
k141_14609_35	SARG|ZP_02903696	38.4	224	252	648	6.75e-41	147
k141_14609_35	SARG|gi|974688082|ref|WP_059271287.1|	38.4	224	252	648	6.75e-41	147
k141_14609_35	SARG|gi|974588181|ref|WP_059178476.1|	34.6	254	252	646	5.79e-39	142
k141_14609_35	SARG|YP_001176128	34.6	254	252	646	5.79e-39	142
k141_14609_35	SARG|gi|754964360|ref|WP_042320280.1|	36.4	228	252	648	3.93e-38	139
k141_14609_35	SARG|gi|749017716|ref|WP_040076354.1|	35.5	234	252	646	5.34e-38	139
k141_14609_35	SARG|gi|757782629|ref|WP_043001213.1|	36.0	228	252	648	5.40e-38	139
k141_14609_46	SARG|gi|446048013|ref|WP_000125868.1|	29.3	229	510	648	1.70e-23	103
k141_14609_46	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.1	203	510	664	4.70e-17	83.2
k141_14609_46	SARG|gb|AAC75271.1|ARO:3003952|yojI	28.2	213	510	547	1.04e-13	72.4
k141_14609_46	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.4	201	510	579	1.71e-11	65.5
k141_14609_46	SARG|gb|AAR96051.1|ARO:3002894|otrC	23.2	319	510	351	2.11e-10	61.2
k141_14609_46	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	23.2	319	510	351	2.11e-10	61.2
k141_14609_46	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.1	199	510	579	3.68e-10	61.2
k141_14609_49	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.6	877	901	1033	8.77e-67	241
k141_14609_49	SARG|gb|AEY83581|ARO:3000510|mupB	23.6	877	901	1033	8.77e-67	241
k141_14609_49	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.5	821	901	1024	5.90e-61	223
k141_14609_49	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.5	821	901	1024	5.90e-61	223
k141_14609_49	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.5	821	901	1024	1.07e-60	223
k141_14609_49	SARG|gb|CAA53189|ARO:3000521|mupA	24.5	821	901	1024	1.07e-60	223
k141_180542_64	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.0	676	653	703	1.17e-170	503
k141_180542_72	SARG|AUI09862.1	38.2	283	269	287	7.20e-54	175
k141_180542_72	SARG|gi|446966005|ref|WP_001043261.1|	34.8	270	269	271	9.36e-40	138
k141_180542_72	SARG|gi|486033774|ref|WP_001505252.1|	34.6	266	269	271	9.36e-40	138
k141_180542_72	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	34.6	266	269	271	2.60e-39	137
k141_180542_72	SARG|gi|638947703|ref|WP_024439711.1|	34.6	266	269	271	3.66e-39	136
k141_180542_72	SARG|DQ464881.1.gene2.p01	34.6	266	269	271	5.14e-39	136
k141_180542_72	SARG|gi|754661150|ref|WP_042043527.1|	34.2	266	269	271	7.23e-39	135
k141_180542_72	SARG|gi|550552396|ref|WP_022631488.1|	34.6	266	269	271	7.23e-39	135
k141_180542_72	SARG|gi|490067892|ref|WP_003970071.1|	34.2	266	269	271	7.23e-39	135
k141_180542_72	SARG|gi|916164813|ref|WP_050960181.1|	34.2	266	269	271	1.02e-38	135
k141_180542_104	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	43.1	123	302	373	1.13e-26	106
k141_180542_118	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	46.7	150	159	164	2.61e-40	132
k141_180542_118	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	44.3	149	159	166	7.88e-40	131
k141_180542_118	SARG|CAE53424	42.6	141	159	169	2.56e-36	122
k141_180542_118	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	40.4	161	159	166	2.67e-35	119
k141_180542_118	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	40.6	160	159	164	1.15e-33	115
k141_180542_118	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	38.7	155	159	162	3.50e-32	111
k141_180542_118	NCBI|WP_130949671.1|1|1|dfrA50|dfrA50|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA50|AMR|diaminopyrimidine	39.5	124	159	158	1.28e-28	102
k141_180542_118	NCBI|WP_000781812.1|1|1|dfrA51|dfrA51|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA51|AMR|diaminopyrimidine	41.6	125	159	158	5.11e-28	100
k141_180542_118	NCBI|WP_040203768.1|1|1|dfrA50|dfrA50|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA50|AMR|diaminopyrimidine	37.9	124	159	158	8.12e-27	97.8
k141_180542_118	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	42.1	140	159	170	2.21e-26	97.1
k141_180542_132	SARG|DQ212986.1.gene8.p01	43.4	350	360	349	2.49e-92	279
k141_180542_132	SARG|gi|405945042|pdb|4FU0|A	43.4	350	360	357	3.19e-92	279
k141_180542_132	SARG|gi|765411304|ref|WP_044689514.1|	43.4	350	360	349	4.98e-92	278
k141_180542_132	SARG|AAF71281	43.1	350	360	349	1.41e-91	277
k141_180542_132	SARG|gi|752682279|ref|WP_041330231.1|	41.5	349	360	349	2.26e-90	274
k141_180542_132	SARG|gi|1028100561|ref|WP_063856696.1|	41.7	348	360	349	1.81e-89	271
k141_180542_132	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	43.8	354	360	341	2.26e-88	268
k141_180542_132	SARG|gb|KTE89608.1|ARO:3003723|vanI	43.7	355	360	348	5.62e-88	268
k141_180542_132	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_5	42.8	360	360	359	2.52e-86	264
k141_180542_132	NCBI|WP_018211347.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	42.5	355	360	345	3.28e-86	263
k141_67851_8	SARG|gi|742378414|ref|WP_038857601.1|	42.5	221	232	647	4.89e-52	177
k141_67851_8	SARG|gi|495004199|ref|WP_007730213.1|	42.5	221	232	647	9.44e-52	176
k141_67851_8	SARG|gi|742409107|ref|WP_038888226.1|	42.5	221	232	647	9.44e-52	176
k141_67851_8	SARG|gi|912614197|ref|WP_050196089.1|	40.2	219	232	648	1.33e-51	176
k141_67851_8	SARG|gi|565651791|ref|WP_023899061.1|	42.1	221	232	647	1.82e-51	175
k141_67851_8	SARG|gi|1020141879|ref|WP_063264839.1|	41.4	222	232	647	3.51e-51	174
k141_67851_8	SARG|gi|742384718|ref|WP_038863845.1|	41.6	221	232	647	4.88e-51	174
k141_67851_8	SARG|gi|696420214|ref|WP_032990021.1|	41.6	221	232	647	6.77e-51	174
k141_67851_8	SARG|gi|671541568|ref|WP_031525212.1|	41.4	220	232	648	6.85e-51	174
k141_67851_8	SARG|YP_001438541	41.6	221	232	647	9.40e-51	173
k141_67851_10	SARG|gi|736472622|ref|WP_034494292.1|	22.6	474	467	648	1.99e-17	84.0
k141_67851_10	SARG|gi|1035670474|ref|WP_064517458.1|	23.5	468	467	648	8.25e-17	82.0
k141_67851_10	SARG|gi|1035717981|ref|WP_064557480.1|	23.5	468	467	648	8.25e-17	82.0
k141_67851_10	SARG|gi|495736522|ref|WP_008461101.1|	22.4	474	467	648	3.41e-16	80.1
k141_67851_10	SARG|gi|746243059|ref|WP_039291473.1|	22.4	474	467	648	3.41e-16	80.1
k141_67851_10	SARG|gi|746253210|ref|WP_039301529.1|	22.4	474	467	648	3.41e-16	80.1
k141_67851_10	SARG|gi|1035706844|ref|WP_064548272.1|	22.8	474	467	648	3.41e-16	80.1
k141_67851_10	SARG|gi|1001720867|ref|WP_061274204.1|	22.4	474	467	648	7.99e-16	79.0
k141_67851_10	SARG|YP_002382193	21.1	473	467	648	3.29e-15	77.0
k141_67851_10	SARG|gi|657888313|ref|WP_029592374.1|	22.6	477	467	648	4.37e-15	76.6
k141_67851_42	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.9	232	221	231	2.69e-38	131
k141_67851_42	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.9	232	221	231	5.35e-38	130
k141_67851_42	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.5	232	221	231	1.06e-37	130
k141_67851_42	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.5	232	221	231	1.50e-37	129
k141_67851_42	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.3	232	221	231	2.12e-37	129
k141_67851_42	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.0	233	221	232	6.08e-37	128
k141_67851_42	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.6	233	221	232	1.70e-36	127
k141_67851_42	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	32.6	221	221	223	5.88e-35	122
k141_67851_42	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	29.3	222	221	225	2.47e-30	110
k141_67851_42	CARD|gb|AAC73788.1|ARO:3003841|kdpE	29.3	222	221	225	2.47e-30	110
k141_67851_44	SARG|gb|AAV85982.1|ARO:3000535|macB	42.7	225	230	644	2.27e-53	180
k141_67851_44	SARG|gi|585349466|ref|WP_024231081.1|	40.7	226	230	648	6.42e-53	179
k141_67851_44	SARG|gi|585345156|ref|WP_024226778.1|	40.7	226	230	648	6.42e-53	179
k141_67851_44	SARG|gi|494938585|ref|WP_007664615.1|	41.6	226	230	647	4.57e-52	177
k141_67851_44	SARG|gi|895898290|ref|WP_048999361.1|	42.2	223	230	646	6.27e-52	176
k141_67851_44	SARG|gi|823291602|ref|WP_047047573.1|	41.8	220	230	648	8.92e-52	176
k141_67851_44	SARG|gi|639209604|ref|WP_024547784.1|	41.9	222	230	648	1.72e-51	175
k141_67851_44	SARG|gi|803568669|ref|WP_046077412.1|	40.0	225	230	648	2.39e-51	175
k141_67851_44	SARG|gi|446110352|ref|WP_000188207.1|	40.0	225	230	648	2.39e-51	175
k141_67851_44	SARG|YP_002382193	40.0	225	230	648	2.39e-51	175
k141_67851_61	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	36.8	201	225	231	6.06e-38	130
k141_67851_61	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.3	201	225	233	1.79e-37	129
k141_67851_61	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.3	201	225	219	2.46e-37	129
k141_67851_61	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.9	233	225	235	5.43e-33	118
k141_67851_61	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.6	223	225	223	1.58e-32	116
k141_67851_61	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	36.3	201	225	225	1.66e-32	116
k141_67851_61	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.5	209	225	233	1.11e-31	114
k141_67851_61	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.7	207	225	231	4.49e-30	110
k141_67851_61	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.0	203	225	225	5.92e-29	107
k141_67851_61	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.0	203	225	225	5.92e-29	107
k141_67851_62	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.2	216	381	364	5.11e-22	95.1
k141_67851_62	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.2	216	381	364	5.11e-22	95.1
k141_67851_62	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.0	214	381	364	2.06e-20	90.5
k141_67851_62	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.0	214	381	364	2.06e-20	90.5
k141_67851_62	CARD|gb|ADM92606.1|ARO:3000549|adeS	23.2	289	381	361	5.73e-19	86.3
k141_67851_70	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.1	274	505	451	2.36e-22	98.6
k141_67851_70	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.5	215	505	359	7.42e-19	87.0
k141_67851_70	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.3	251	505	364	3.59e-17	82.0
k141_67851_70	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.3	251	505	364	3.59e-17	82.0
k141_67851_70	CARD|gb|AEX49906.1|ARO:3003583|basS	24.7	227	505	477	2.11e-14	74.3
k141_67851_71	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.1	224	232	231	1.84e-64	199
k141_67851_71	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.6	231	232	232	1.24e-62	194
k141_67851_71	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.1	231	232	232	3.52e-62	193
k141_67851_71	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	225	232	232	2.83e-61	191
k141_67851_71	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.2	230	232	231	3.14e-60	188
k141_67851_71	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.7	230	232	231	8.90e-60	187
k141_67851_71	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.7	232	232	233	9.46e-60	187
k141_67851_71	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.3	234	232	235	1.42e-59	186
k141_67851_71	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.5	227	232	228	6.54e-59	184
k141_67851_71	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.2	230	232	231	1.43e-58	184
k141_162341_4	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	44.0	232	233	230	1.02e-58	184
k141_162341_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.6	231	233	229	5.61e-58	182
k141_162341_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.9	230	233	232	1.40e-56	179
k141_162341_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.9	230	233	232	1.40e-56	179
k141_162341_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	232	233	231	6.18e-55	174
k141_162341_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.1	236	233	235	1.39e-54	174
k141_162341_4	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	40.7	231	233	231	1.98e-53	171
k141_162341_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.0	227	233	231	5.62e-53	169
k141_162341_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.5	232	233	231	6.36e-52	167
k141_162341_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	232	233	231	6.36e-52	167
k141_162341_5	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	32.3	248	308	357	1.12e-32	122
k141_162341_5	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	32.3	248	308	357	1.12e-32	122
k141_162341_5	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.9	226	308	381	8.37e-30	115
k141_162341_5	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.9	226	308	381	8.37e-30	115
k141_162341_5	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.2	243	308	380	8.02e-29	112
k141_162341_5	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.2	243	308	380	8.02e-29	112
k141_162341_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.8	270	308	365	3.28e-28	110
k141_162341_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.1	269	308	370	4.87e-28	110
k141_162341_5	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.0	217	308	368	1.25e-27	109
k141_162341_5	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.5	217	308	367	3.26e-27	108
k141_162341_7	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	61.6	307	308	307	6.32e-137	389
k141_162341_7	SARG|gi|445996719|ref|WP_000074574.1|	54.1	303	308	309	4.10e-109	318
k141_162341_7	SARG|gi|542061059|gb|ERI11611.1|	54.8	303	308	316	5.18e-109	318
k141_162341_7	SARG|gi|500194536|ref|WP_011867743.1|	54.5	303	308	306	5.26e-109	318
k141_162341_7	SARG|gi|445996729|ref|WP_000074584.1|	54.1	303	308	309	8.24e-109	317
k141_162341_7	SARG|gi|445996710|ref|WP_000074565.1|	53.8	303	308	309	8.24e-109	317
k141_162341_7	SARG|YP_001373621	53.8	303	308	318	1.58e-108	317
k141_162341_7	SARG|gi|445996714|ref|WP_000074569.1|	53.8	303	308	309	1.66e-108	317
k141_162341_7	SARG|gi|447195835|ref|WP_001273091.1|	54.5	303	308	306	2.12e-108	316
k141_162341_7	SARG|gi|446110087|ref|WP_000187942.1|	53.8	303	308	309	2.35e-108	316
